Drugs /

mitomycin

Back to Drugs List

Overview

Generic Name(s):
mitomycin
Trade Name(s):
Mitolem, Mitocin-C, Mutamycin, Mitozytrex, Ametycine, Mito-Medac, and Mutamycine
NCI Definition [1]:
A methylazirinopyrroloindoledione antineoplastic antibiotic isolated from the bacterium Streptomyces caespitosus and other Streptomyces bacterial species. Bioreduced mitomycin C generates oxygen radicals, alkylates DNA, and produces interstrand DNA cross-links, thereby inhibiting DNA synthesis. Preferentially toxic to hypoxic cells, mitomycin C also inhibits RNA and protein synthesis at high concentrations. (NCI04)

Clinical Trials

View Clinical Trials for mitomycin

Mitomycin has been investigated in 4 clinical trials, of which 4 are open and 0 are closed. Of the trials investigating mitomycin, 3 are phase 2 (3 open) and 1 is phase 3 (1 open).

CDKN2A No Expression, CDKN2A Overexpression, and HPV Positive are the most frequent biomarker inclusion criteria for mitomycin clinical trials.

Anal canal squamous cell carcinoma, anal margin squamous cell carcinoma, and bladder urothelial carcinoma are the most common diseases being investigated in mitomycin clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Mitomycin
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating mitomycin and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
jelmyto, (1as,8s,8ar,8bs)-6-amino-8-[[(aminocarbonyl)oxy]methyl]-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methylazirino[2',3':3,4]pyrrolo[1,2-a]indole-4,7-dione, [1as-(1a alpha,8beta,8a alpha,8b alpha)]-6-amino-8-[[(aminocarbonyl)oxy]methyl]-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methylazirino[2',3':3,4]pyrrolo[1,2-a]indole-4,7-dione, nci-c04706, mitomycin c, mitocin, mito, mito-c, mitosol, mitomycin-x, mitomycine c, Mutamycine, Mito-Medac, Mitolem, Mitocin-C, Ametycine, Mutamycin, Mitozytrex
Drug Categories [2]:
Alkylating agents, Antitumor antibiotics
NCIT ID [1]:
C1820

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.